Sugi Predict

Sugi Predict / Compounds / SCHEMBL2556095

SCHEMBL2556095

SCHEMBL2556095

O=Cc1ccc(-c2ccc(Cl)c(C(=O)O)c2)o1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LDHA P00338 1/20 0.72
▸ LDHB P07195 1/20 0.72
▸ HAO1 Q9UJM8 1/20 0.72
▸ ALDH1A1 P00352 10/20 0.67
▸ POLB P06746 8/20 0.67
▸ LMNA P02545 1/20 0.67
▸ SMN1; SMN2 Q16637 1/20 0.64
▸ KDM4E B2RXH2 10/20 0.62
▸ TDP1 Q9NUW8 9/20 0.62
▸ KMT2A Q03164 8/20 0.62
▸ L3MBTL1 Q9Y468 7/20 0.62
▸ APEX1 P27695 4/20 0.62
▸ CTDSP1 Q9GZU7 4/20 0.62
▸ MEN1 O00255 7/20 0.61
▸ MAPT P10636 6/20 0.61
▸ GAA P10253 3/20 0.61
▸ HPGD P15428 1/20 0.61
▸ ALOX12 P18054 1/20 0.61
▸ NPSR1 Q6W5P4 1/20 0.61
▸ TTR P02766 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15331986 0.88 LDHA (0.68) LDHALDHBHAO1ALDH1A1POLB
SCHEMBL19654561 0.87 KDM4E (0.61) LDHALDHBHAO1ALDH1A1POLB
SCHEMBL1435313 0.84 LDHA (1.00) LDHALDHBHAO1ALDH1A1POLB
SCHEMBL30343475 0.84 LDHA (1.00) LDHALDHBHAO1ALDH1A1POLB
SCHEMBL2553518 0.82 LDHA (0.72) LDHALDHBHAO1ALDH1A1POLB
SCHEMBL1806482 0.81 ALDH1A1 (0.57) LDHALDHBHAO1ALDH1A1POLB
SCHEMBL1435328 0.81 LDHA (0.78) LDHALDHBHAO1ALDH1A1POLB
SCHEMBL18920608 0.80 ALDH1A1 (0.83) LDHALDHBHAO1ALDH1A1POLB
SCHEMBL18920689 0.79 KDM4E (0.60) LDHALDHBHAO1ALDH1A1POLB
SCHEMBL5164488 0.79 KMT2A (0.71) ALDH1A1POLBSMN1; SMN2KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3684354-B1 XPA INHIBITOR COMPOUNDS AND THEIR USE UNIV INDIANA RES & TECH CORP (US) 2023-11-15 — — EP disclosed
EP-3684354-B1 XPA INHIBITOR COMPOUNDS AND THEIR USE UNIV INDIANA RES & TECH CORP (US) 2023-11-15 — — EP disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 — — US disclosed
US-20220089577-A1 KU INHIBITORS AND THEIR USE UNIV INDIANA RES & TECH CORP (US) 2022-03-24 — — US disclosed
US-20220089577-A1 KU INHIBITORS AND THEIR USE UNIV INDIANA RES & TECH CORP (US) 2022-03-24 — — US disclosed
EP-3463371-B1 KU INHIBITORS AND THEIR USE UNIV INDIANA RES & TECH CORP (US) 2022-02-23 — — EP disclosed
US-11225655-B2 Bi-functional complexes and methods for making and using such complexes NUEVOLUTION A/S (DK) 2022-01-18 — — US disclosed
US-11207296-B2 XPA inhibitor compounds and their use INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2021-12-28 — — US disclosed
US-11207296-B2 XPA inhibitor compounds and their use INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2021-12-28 — — US disclosed
US-20200308154-A1 KU INHIBITORS AND THEIR USE INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2020-10-01 — — US disclosed
US-20130281324-A1 BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2013-10-24 — — US disclosed
EP-2558577-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES Nuevolution A/S (DK) 2013-02-20 — — EP disclosed
WO-2011127933-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2011-10-20 — — WO disclosed
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 — — US disclosed
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 — — US disclosed
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 — — US disclosed
WO-2010148351-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-12-23 — — WO disclosed
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 — — US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 — — WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089577-A1 KU INHIBITORS AND THEIR USE ZFR, XRCC6, ZFX LDHA 3493/4885LDHB 3193/4885HAO1 2007/4885
US-11207296-B2 XPA inhibitor compounds and their use XPOT, XPA, ERCC4 LDHA 2521/4885LDHB 2688/4885HAO1 2806/4885
US-20200308154-A1 KU INHIBITORS AND THEIR USE ZFR, XRCC6, ZFX LDHA 3493/4885LDHB 3193/4885HAO1 2007/4885
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM2, PIM1, CDK2 LDHA 2006/4885LDHB 2255/4885HAO1 4070/4885
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 LDHA 3775/4885LDHB 4014/4885HAO1 3198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.